Euroscreen Appoints François Roman, Ph.D., as Vice President of Research and Development

Euroscreen S.A. today announced the appointment of François Roman, Ph.D. to the position of Vice President of Research and Development. Dr. Roman joins Euroscreen with more than 25 years experience in Drug Discovery, including senior positions with Laboratoires Servier, Laboratoires Jouveinal, Parke- Davis and Pfizer PGRD.

Brussels, Belgium (PRWEB) March 10, 2004 -- Euroscreen S.A. today announced the appointment of François Roman, Ph.D. to the position of Vice President of Research and Development. Dr. Roman joins Euroscreen with more than 25 years experience in Drug Discovery, including senior positions with Laboratoires Servier, Laboratoires Jouveinal, Parke- Davis and Pfizer PGRD.

"Euroscreen is continuing to solidify its infrastructure by adding experienced individuals in key positions to meet its long-term objectives. Dr. Roman brings to Euroscreen 25 years of experience in creating and managing pharmaceutical R&D teams that performed cutting edge research in Drug Discovery," said Pierre Nokin, Ph.D., Euroscreen's President and CEO. "Using Euroscreen's GPCR science and technologies, Dr. Roman will drive our drug development programs and enter into new collaborations with companies to leverage our biology and our patent rights to partner new drug targets and candidates."

Dr. Roman previously served as the Director of HTS and Assay Development at Pfizer PGRD France. Prior to his position at Pfizer, Dr Roman was the Head of Molecular Pharmacology at Parke-Davis France, Director of Biochemistry Department at Jouveinal Laboratoires, France, and Head of Neurochemistry unit at Laboratoires Servier, France. During more than 25 years, Dr Roman has been involved in many discovery programs and has managed various projects in a broad range of therapeutic areas including metabolic, CNS, gastrointestinal, pulmonary and inflammatory diseases.

Dr. Roman holds a Ph.D. in Biochemistry from the University of Paris VI, France and has more than 40 publications and 35 patents.

Euroscreen is a world class G protein-coupled receptor (GPCR) research and HTS products company with patented AequoScreen cellular assay technology to provide new, innovative solutions to GPCR discovery. The company has several important drug targets and patent applications such as pivotal patent rights covering the use of CCR5 for HIV applications. Euroscreen has corporate partnerships with Solvay, Merck & Co., Pfizer Inc and UCB as well as licensing agreements with the Brussels University, the University of Georgia Research Foundation, the University of Toronto and many other universities. More information about Euroscreen's products and services can be found at www.euroscreen.be.

Contact:
Pierre Nokin, Ph.D.
President and Chief Executive Officer
Euroscreen S.A.
(32) 71 348 500